Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1

NCT06222827 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Facioscapulohumeral Muscular Dystrophy 1

Interventions

DRUG: Satralizumab Prefilled Syringe
DRUG: Placebo Comparator

Sponsor

Centre Hospitalier Universitaire de Nice